Patients seek US ban on fibroid removal devices

July 11, 2014 by Matthew Perrone

More than a dozen Americans—including cancer patients, their family members and physicians—called on U.S. health regulators on Friday to block the use of electronic surgical tools used to remove fibroids, but which can inadvertently spread cancer throughout the body.

An expert panel of Food and Drug Administration advisers heard impassioned pleas from women with cancer and family members of deceased patients who said they were unaware of the cancer risks of the popular technique for treating fibroids by grinding the tissue and removing it through a small incision in the abdomen. The devices are also frequently used in hysterectomies, or removal of the uterus, a common approach for preventing the growth of future fibroids.

Surgeons developed the technique as an alternative to traditional surgery, which requires a larger incision that often results in more bleeding and longer hospital stays.

Doctors have long acknowledged the risk of accidentally spreading undetected cancer with the electronic devices, known as power morcellators. But the FDA has convened a two-day meeting after calculating that the problem may occur more often than previously thought. The agency said in April that as many as 1 in 351 women may have undetected uterine cancer that can be disturbed by the technique. Previous estimates put the rate closer to 1 in 7,000.

"Would you permit your wife or sister to undergo a procedure that has a one in 351 chance of spreading cancer throughout the body?" Colleen Daley asked the FDA panel of obstetricians and gynecologists. Daley's sister, Patricia Marie Daley, died in 2011 of leiomyosarcoma, a uterine cancer that spread to her lungs after undergoing treatment with power morcellators.

Sarah Salem, who was diagnosed with the disease in 2012 after undergoing power morcellation, said surgeons should not be blamed for failing to detect cancers.

"But what we refuse to accept is the senseless and unethical risk that our surgeons took to allow the spread of our cancer," she said.

The FDA approved the first electronic morcellators in 1995 and about two dozen have been approved in U.S. since then. The devices were cleared through an abbreviated review process because they were deemed similar to manual surgical devices long on the market.

The panel of FDA advisers is scheduled to discuss a number of potential options for reducing the risks with the devices, including:

— identifying patients who may be at increased risk for uterine cancer

— adding new warnings to the morcellators' labeling about cancer spread

— using protective bags to collect uterine tissue so it doesn't spread into the abdomen.

— requirements for increased safety testing of the devices

Fibroids are non-cancerous growths in the uterus that can cause severe pain, heavy bleeding, and bladder and bowel dysfunction, mostly among women in their late 30s and 40s. It's unclear what causes the tumor-like growths—which can grow as large as cantaloupes—but they account for an estimated 240,000 of the 600,000 annual hysterectomies in the U.S. At least 50,000 U.S. women undergo hysterectomy using the power morcellation technique.

Hysterectomy is a key treatment because it is the only way to ensure that fibroids do not return. Myomectomy, surgery that removes fibroids while leaving the uterus intact, is recommended for women who still want to become pregnant.

Explore further: J&J halts sale of electric fibroid removal devices

Related Stories

J&J halts sale of electric fibroid removal devices

April 30, 2014
Johnson & Johnson is halting sales of devices used to remove growths in the uterus following a government warning that the electronic surgical tools can inadvertently spread cancer to other parts of the body.

FDA warns of risks with fibroid removal procedure (Update)

April 17, 2014
The Food and Drug Administration is warning American women that a device-assisted procedure for treating fibroids could inadvertently spread cancer from the uterus to other parts of the body.

FDA approves first pre-surgical breast cancer drug

September 30, 2013
Federal health officials say they have approved a biotech drug from Roche as the first medicine labeled for the treatment of breast cancer before surgery.

FDA panel narrowly backs DNA colon cancer test

March 26, 2014
A panel of Food and Drug Administration advisers has narrowly backed an experimental blood test that uses patients' DNA to help screen for colon cancer.

FDA advisers back Exact Sciences colon cancer test

March 27, 2014
A panel of Food and Drug Administration advisers has voted to endorse an experimental stool test that uses DNA to detect colon cancer and precancerous growths.

Fibroids are common problem for women

April 1, 2014
Uterine fibroids are very common, occurring in as many as 50 percent of women in their reproductive years and up to two-thirds of women by the time they go through menopause. While many fibroids cause no problems and require ...

Recommended for you

What can salad dressing tell us about cancer? Think oil and vinegar

September 20, 2018
Researchers led by St. Jude Children's Research Hospital scientists have identified another way the process that causes oil to form droplets in water may contribute to solid tumors, such as prostate and breast cancer. The ...

Novel biomarker found in ovarian cancer patients can predict response to therapy

September 20, 2018
Despite months of aggressive treatment involving surgery and chemotherapy, about 85 percent of women with high-grade wide-spread ovarian cancer will have a recurrence of their disease. This leads to further treatment, but ...

Testing fluorescent tracers used to help surgeons determine edges of breast cancer tumors

September 20, 2018
A team of researchers with members from institutions in The Netherlands and China has conducted a test of fluorescent tracers meant to aid surgeons performing tumor removal in breast cancer patients. In their paper published ...

Cancer immunotherapy might benefit from previously overlooked immune players

September 20, 2018
Cancer immunotherapy—efforts to boost a patient's own immune system, allowing it to better fight cancer cells on its own—has shown great promise for some previously intractable cancers. Yet immunotherapy doesn't work ...

New way to target advanced breast cancers

September 20, 2018
A cytokine signature found in certain kinds of breast cancer cells can not only serve as a diagnostic tool for HER2-negative cancers but also offer an effective treatment target.

Understanding epilepsy in pediatric tumors

September 20, 2018
Pediatric brain tumors are characterized by frequent complications due to intractable epilepsy compared to adult brain tumors. However, the genetic cause of refractory epilepsy in pediatric brain cancer has not been elucidated ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.